Board of Directors
|
Paul Pommier, MBA Chairman of the Board Paul Pommier spent over 25 years at National Bank Financial, his last position being Senior Executive Vice President, Corporate and Government Finance. Throughout his career, he oversaw public and private financings, mergers and acquisitions, as well as the marketing of investment offerings. Retired since 1997, Mr. Pommier was appointed Chairman of the Board of Theratechnologies in 2007. |
 |
|
John-Michel T. Huss, MBA President and Chief Executive Officer John-Michel T. Huss brings more than 20 years of global experience in the pharmaceutical industry to Theratechnologies. He began his career at Merck & Co., occupying various sales and marketing positions in the United States and in Europe. In 1996, he accepted an International Product Manager position at the headquarters of F. Hoffman-La Roche, in Basel. Mr. Huss joined Sanofi-Synthelabo GmbH in 1999, where he held positions of increasing responsibility in Germany and in Canada. He was appointed General Manager of the Swiss subsidiary at sanofi-aventis in 2007, and in 2009 was promoted to the position of Chief of Staff, Office of the CEO, in Paris. |
 |
|
Luc Tanguay, M.Sc., CFA Senior Executive Vice President and Chief Financial Officer Luc Tanguay has been active in the biotechnology industry for over 15 years. As a member of Senior Management at Theratechnologies since 1996, he has contributed to the Company’s growth by facilitating access to public and private capital funding. Prior to joining Theratechnologies, Mr. Tanguay had a successful career in investment banking at National Bank Financial. |
 |
|
Gilles Cloutier, Ph.D. Corporate Director Gilles Cloutier has over 30 years of experience in the pharmaceutical industry including five years with contract research organizations, providing strategic support to the biotechnology and pharmaceutical industry. Dr. Cloutier has also held key positions with large North American pharmaceutical companies where he developed expertise in clinical research. His experience includes the development and approval of several drugs in Canada, the United States and Europe. |
 |
|
Robert G. Goyer, Ph.D. Emeritus Professor, Faculty of Pharmacy of Université de Montréal Robert Goyer has over 40 years of experience in the pharmaceutical field. Former President of Jouveinal Canada, Dr. Goyer is also a former Dean of the Faculty of Pharmacy of Université de Montréal. Recognized for his broad expertise in drug development, Dr. Goyer has served on the boards of several companies and governmental organizations, such as Health Canada’s Therapeutic Products Directorate, the Régie de l’assurance maladie du Québec and the Conseil du médicament du Québec. |
 |
|
Gérald A. Lacoste, Q.C. Corporate Director Gérald Lacoste is a lawyer with extensive experience in the fields of securities regulation, corporate finance and corporate governance. He was previously Chairman of the Quebec Securities Commission (now known as the Autorité des marchés financiers) and was also President and CEO of the Montreal Stock Exchange. Mr. Lacoste is a member of the North American Free Trade Agreement (NAFTA) arbitration panel. |
 |
|
Bernard Reculeau Corporate Director Bernard Reculeau brings over 25 years of pharmaceutical industry experience to Theratechnologies. Mr. Reculeau has extensive hands-on management experience in commercial activities, cumulating close to 15 years in pharmaceutical operations, notably in France where he successfully ran the operations for Rhône-Poulenc and Rhône-Poulenc Rorer. From 2006 to 2009, he was President of CIS Bio, a French company specializing in biomedical technologies. |
 |
|
Jean-Denis Talon Chairman, Axa Canada Jean-Denis Talon had a successful career with AXA Insurance over a period of more than 20 years ultimately becoming President and Chief Executive Officer. He is currently Chairman of the Board of AXA Canada. Mr. Talon is also former President of the Financial Affairs Committee at the Insurance Bureau of Canada. |
 |